RECRUITING

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Description

This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.

Conditions

Head and Neck CancerLocally Advanced Head and Neck Carcinoma
Talk to us

Related Conditions:

Head and Neck CancerLocally Advanced Head and Neck Carcinoma

Study Overview

On this page

Study Details

Study overview

This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.

Phase I/II Trial of Gabapentin Plus Ketamine for Prevention and Treatment of Acute and Chronic Pain in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Condition
Head and Neck Cancer
Intervention / Treatment

-

Contacts and Locations

Nashville

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically proven cancer of the head and neck cancer
  • * Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
  • * Planned primary or adjuvant radiation or chemoradiation therapy
  • * Willing and able to provide informed consent
  • * ECOG PS 0-2
  • * Age ≥ 21 years
  • * English speaking
  • * Currently on gabapentin or ketamine
  • * Prior non-tolerance of gabapentin or ketamine
  • * Unable to administer ketamine intranasally due to anatomical restrictions
  • * History of seizure disorder
  • * History of schizophrenia
  • * History of increased intracranial pressure
  • * Glomerular filtration rate \<30 mL/min/1.73 m2

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Natalie Lockney,

Natalie Lockney, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt-Ingram Cancer Center

Study Record Dates

2026-12-31